World News: 16:05 GMT Wednesday 11th July 2018. [Alliance for Regenerative Medicine via Globe Newswire via SPi World News]
BRUSSELS, Belgium and WASHINGTON, D.C., July 11, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing multiple stakeholder groups comprising the cell and gene therapy and broader regenerative medicine and ATMP sector, today published its position in response to the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU (COM(2018) 51 final).
ARM’s position statement, available , recognizes the benefit of the proposed regulation, which would require joint clinical assessments to be carried out for many medicinal products undergoing the central marketing authorization. These benefits include increased international harmonization and reduced duplication of efforts when companies apply for HTA of their products; a positive impact on time to market; and the potential for better alignment from Member States on issues such as clinical evidence requirements, selection of comparator(s), and design of studies.In the statement, ARM also makes three recommendations intended to ensure the success of the regulation in attaining the full impact of the benefits listed above. These recommendations include:
The proposed Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU is available .
About the Alliance for Regenerative Medicine:
The Alliance for Regenerative Medicine (ARM) is a global, multi-stakeholder organization that promotes innovation, growth, and delivery of transformative treatments or cures for patients suffering from chronic, debilitating, and often life-threatening diseases, many of which are rare diseases. ARM convenes all stakeholders with an interest in regenerative and advanced therapies to provide a unified voice for our 290+ member organizations, including companies – especially small- to medium-sized enterprises (SMEs); academic/research institutions; non-profit organizations; patient advocacy organizations, and other members of the global advanced therapies community. The organization’s aim is to connect all parts of the innovation lifecycle to address current unmet medical needs of patients, particularly through supporting commercialization objectives via legislative and policy frameworks that enable next generation therapies to reach those who need them. To learn more about ARM, visit .
The Alliance for Regenerative Medicine
202 213 7086
Globe Newswire: 16:05 GMT Wednesday 11th July 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.